



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2407959 C 2013/06/11

(11)(21) **2 407 959**

(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 2001/04/30
(87) Date publication PCT/PCT Publication Date: 2001/11/08
(45) Date de délivrance/Issue Date: 2013/06/11
(85) Entrée phase nationale/National Entry: 2002/11/01
(86) N° demande PCT/PCT Application No.: EP 2001/004887
(87) N° publication PCT/PCT Publication No.: 2001/083543
(30) Priorité/Priority: 2000/05/03 (EP00109422.6)

(51) Cl.Int./Int.Cl. *C12N 15/12* (2006.01),
C07H 21/02 (2006.01), *C07K 14/435* (2006.01),
C07K 14/475 (2006.01), *C07K 16/18* (2006.01),
C07K 19/00 (2006.01), *C12N 15/63* (2006.01),
C12N 15/66 (2006.01), *C12Q 1/68* (2006.01),
G01N 33/53 (2006.01)

(72) Inventeur/Inventor:
DUCKER, KLAUS, DE

(73) Propriétaire/Owner:
MERCK PATENT GESELLSCHAFT MIT
BESCHRAENKTER HAFTUNG, DE

(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : GENE HUMAIN DU TYPE WINGLESS
(54) Title: HUMAN WINGLESS-LIKE GENE

(57) **Abrégé/Abstract:**

Wnt-8D polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Wnt-8D polypeptides and polynucleotides in diagnostic assays.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 November 2001 (08.11.2001)

PCT

(10) International Publication Number
WO 01/83543 A1

- (51) International Patent Classification⁷: **C07K 14/435**, C12N 15/66, 15/63, C07K 16/18, G01N 33/53, C07K 14/475
- (74) Common Representative: **MERCK PATENT GMBH**; Frankfurterstrasse 250, 64293 Darmstadt (DE).
- (21) International Application Number: PCT/EP01/04887
- (81) Designated States (*national*): CA, JP, US.
- (22) International Filing Date: 30 April 2001 (30.04.2001)
- (84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).
- (25) Filing Language: English
- (26) Publication Language: English
- Published:**
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
— with sequence listing part of description published separately in electronic form and available upon request from the International Bureau
- (30) Priority Data: 00109422.6 3 May 2000 (03.05.2000) EP
- (71) Applicant (*for all designated States except US*): **MERCK PATENT GMBH** [DE/DE]; Frankfurter Strasse 250, 64293 Darmstadt (DE).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): **DÜCKER, Klaus** [DE/DE]; Ettesterstrasse 5, 64291 Darmstadt (DE).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/83543 A1

(54) Title: HUMAN WINGLESS-LIKE GENE

(57) Abstract: Wnt-8D polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Wnt-8D polypeptides and polynucleotides in diagnostic assays.

HUMAN WINGLESS-LIKE GENE

Field of the Invention

5 This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides sometimes hereinafter referred to as „wingless/int 8D (Wnt-8D)“, to their use in diagnosis and in identifying compounds that may be agonists, antagonists that are potentially useful in therapy, and to production of such polypeptides and polynucleotides.

Background of the Invention

10 The drug discovery process is currently undergoing a fundamental revolution as it embraces "functional genomics", that is, high throughput genome- or gene-based biology. This approach as a means to identify genes and gene products as therapeutic targets is rapidly superceding
15 earlier approaches based on "positional cloning". A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.

20 Functional genomics relies heavily on high-throughput DNA sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug
25 discovery.

Summary of the Invention

30 The present invention relates to Wnt-8D, in particular Wnt-8D polypeptides and Wnt-8D polynucleotides, recombinant materials and methods for their production. Such polypeptides and polynucleotides are of interest in relation to methods of treatment of certain diseases, including,

26474-677

- 2 -

but not limited to, asthma, alzheimer, cancer, cardiomyopathies, depression, schizophrenia, general psychotic disorders, ischemia, stroke, wound healing, kidney diseases, lung disorders, aberrant apoptosis, tissue remodeling, stem cell therapies, hereinafter referred to as “diseases of the invention”. In a further aspect, the invention relates to methods for identifying agonists and antagonists (e.g., inhibitors) using the materials provided by the invention, and treating conditions associated with Wnt-8D imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate Wnt-8D activity or levels.

10 In a particular embodiment, the invention relates to an isolated human wingless/int 8D (Wnt-8D) polypeptide comprising the polypeptide sequence of SEQ ID NO:2.

In another embodiment, the invention relates to an isolated polynucleotide encoding human wingless/int 8D (Wnt-8D), comprising
15 polynucleotides from nucleotide positions 100 to 1155 of SEQ ID NO: 1.

In another embodiment, the invention relates to an isolated polynucleotide encoding a human wingless/int 8D (Wnt-8D) polypeptide, wherein said polypeptide comprises the polypeptide sequence of SEQ ID NO: 2.

In another embodiment, the invention relates to an isolated
20 polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the polynucleotide of SEQ ID NO:1; (b) the polynucleotide of SEQ ID NO:1; (c) a polynucleotide comprising a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2; and (d) a polynucleotide encoding the polypeptide of SEQ ID NO:2.

In another embodiment, the invention relates to an expression vector
25 comprising the isolated polynucleotide as described above.

26474-677

- 2a -

In another embodiment, the invention relates to an expression system comprising a polynucleotide capable of producing a polypeptide as described above when said expression system is present in a compatible host cell.

5 In another embodiment, the invention relates to a recombinant host cell comprising the expression vector as described above or a membrane thereof expressing the polypeptide as described above.

In another embodiment, the invention relates to a process for producing a polypeptide as described above comprising the step of culturing a host cell as described above under conditions sufficient for the production of said polypeptide and
10 recovering the polypeptide from the culture medium.

In another embodiment, the invention relates to a fusion protein comprising the Immunoglobulin Fc-region and a polypeptide as described above.

In another embodiment, the invention relates to an antibody immunospecific for the polypeptide as described above.

15 In another embodiment, the invention relates to a method for screening to identify compounds that stimulate or inhibit the function or level of the polypeptide as described above comprising a method selected from the group consisting of: (a) measuring or, detecting, quantitatively or qualitatively, the binding of a candidate compound to the polypeptide, or to the cells or membranes expressing the
20 polypeptide, or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound; (b) measuring the competition of binding of a candidate compound to the polypeptide, or to the cells or membranes expressing the polypeptide, or a fusion protein thereof in the presence of a labeled competitor; (c) testing whether the candidate compound results in a signal generated by
25 activation or inhibition of the polypeptide, using detection systems appropriate to the cells or cell membranes expressing the polypeptide; (d) mixing a candidate compound with a solution containing a polypeptide as described above, to form a

26474-677

- 2b -

mixture, measuring activity of the polypeptide in the mixture, and comparing the activity of the mixture to a control mixture which contains no candidate compound; and (e) detecting the effect of a candidate compound on the production of mRNA encoding said polypeptide or said polypeptide in cells, using for instance,

5 an ELISA assay.

26474-677

- 2c -

Description of the Invention

In a first aspect, the present invention relates to Wnt-8D polypeptides. Such polypeptides include:

- 5 (a) a polypeptide encoded by a polynucleotide comprising the sequence of SEQ ID NO:1;
- (b) a polypeptide comprising a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2;
- 10 (c) a polypeptide comprising the polypeptide sequence of SEQ ID NO:2;
- (d) a polypeptide having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2;
- (e) the polypeptide sequence of SEQ ID NO:2; and
- 15 (f) a polypeptide having or comprising a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polypeptide sequence of SEQ ID NO:2;
- (g) fragments and variants of such polypeptides in (a) to (f).

20 Polypeptides of the present invention are believed to be members of the wingless/int family of polypeptides. The mouse int-1 gene was originally identified as a locus activated by mouse mammary tumor virus insertion. Cloning and sequencing of the mouse gene showed its high degree of

homology with the *Drosophila* segment polarity gene *wingless*, a gene involved in pattern formation in segments of the developing fly (McMahon A.P. and Moon R.T., *Development* 107 Suppl., 161-167, 1989). In the last few years it has been recognized that *int-1* and *Wingless* belong to a large family of related glyco-proteins found in vertebrates and invertebrates. In recognition of this, members of this family have been renamed Wnts, an amalgam of *int* and *Wingless*.

Wnt signaling regulates cell proliferation and differentiation in species as divergent as nematodes, flies, frogs, and humans (for a review see Cadigan, K.M. and Nusse, R., *Genes & Dev.* 11, 3286-3305, 1997). Wnt perception is mediated by members of the frizzled 7TM domain receptor family. Cytoplasmically the signal is transduced via a complex protein cluster incorporating beside other proteins *dishevelled*, *axin*, *GSK-3*, *adenomatous polyposis coli* (APC), β -catenin/*armadillo* and members of the HMG-protein family *LEF/TCF* (for a recent review about wnt signaling refer to Pfeifer, M. and Polakis, P., *Science* 287, 1606-1609, 2000).

A plethora of experimental results point to various human diseases, in which aberrant wnt signaling has been identified. The most prominent disease association is between wnt signaling and cancer. The proto-oncogene *int-1* had been identified based on its scorable phenotype, which is a virus-induced ectopic expression causing mammary tumors. Accordingly, *Wnt2*, *Wnt4*, *Wnt7b* and *Wnt10b* have been associated with human breast carcinomas (Huguet, E.L. et al., *Cancer Res.* 54, 2615-2621, 1994; Bui, T.D. et al., *Oncogene* 14, 1249-1253, 1997). Human colorectal cancers have also clearly been associated with aberrant wnt signaling, although quite often these tumors are associated with mutations not in a wnt gene (or its aberrant expression), but in components of the downstream intracellular signal transduction cascade (mainly mutations in APC or β -catenins; Smith, K. et al., *Br. J. Cancer* 81, 496-502, 1999; Laurent-Puig P. et al., *Eur. J. Cancer Prev. Suppl*, S39-47, 1999). Meanwhile aberrant wnt signaling has been found in tumor tissues ranging from lung, breast, prostate carcinomas, melanomas (Iozzo, R.V. et al., *Cancer Res.* 55, 3495-3499, 1995), medulloblastomas

(Huang, H. et al., Am. J. Pathol. 156, 433-437, 2000), sporadic hepatoblastoma.(Sato, S. et al., Nat. Genet. 24, 245-250, 2000; Jeng, Y. et al., Cancer Lett. 152, 45-51, 2000) or endometrial tumors (Bui, T.D. et al., Br. J. Cancer 75, 1131-1136, 1997). Interestingly, Dkk genes -known secreted inhibitors of wnt signaling- show high level of expression in differentiated tissues and are downregulated in tumor tissues (Wang, J. et al., Oncogene 19, 1843-1848, 2000; Tsuji, T. et al., Biochem. Biophys. Res. Commun. 268, 20-24, 2000), furthering the role of wnt signaling in proliferation.

Beside this cancer association, wnt signaling plays a fundamental role in development. Therefore, many tissue remodelling processes in the adult could be affected by this signaling cascade. A function of wnt signaling has for example been shown for myogenesis (for a review see Cossu, G. et al., EMBO J. 18, 6867-6872, 1999), heart (Jaspard, B. et al., Mech. Dev. 90, 263-267, 2000) and kidney formation (Vainio, S.J. et al., Int. J. Dev. Biol. 43, 419-423, 1999), brain development as well as axonal remodelling and synaptogenesis (Salinas, P.C. et al., Biochem. Soc. Symp. 65, 101-109, 1999; Burden, S.J. et al., Cell 100, 495-497, 2000). Interestingly, wnt signaling seems to be attenuated in failing heart (Schuhmann, H. et al., Cardiovasc. Res. 45, 720-728, 2000).

Another aspect of wnt signaling is its possible association with psychotic disorders. Lithium ions have been used for over 100 years to treat depression (for a recent review see Williams, R.S. and Harwood, A.J., Trends Pharmacol. Sci. 21, 61-64, 2000 and references therein). Although the molecular action of this therapy is still not known, evidence has been collected that inhibition of an cytoplasmic kinase, glycogen synthase kinase-3 β (GSK3 β) could represent the actual target of lithium ions (Chen, G. et al., J. Neurochem. 72, 1327-1330, 1999). Inhibition of exactly this kinase is one of the main activities of wnt signaling, and supports the idea that aberrant wnt signaling is involved in bipolar disorders. This assumption is further supported by an indirect approach, where the chromosomal locations of some members of the wnt signaling pathway have been assigned to regions known to harbor susceptibility to

bipolar disorder and schizophrenia as well as disorders of neurodevelopmental origin (Rhoads, A.R. et al., Mol. Psychiatry 4, 437-442, 1999). GSK-3 β function is inhibited upon wnt signaling, which leads to elevated levels of β -catenin in the cytoplasm and in the nucleus where it stimulates gene expression in conjunction with members of the HMG-protein group (see above). Interestingly, a recent publication claims that cytoplasmic catenin levels is reduced in hippocampal CA3 and CA4 subregions among schizophrenic subjects (Cotter, D. et al., Neuroreport 9, 1379-1383, 1998).

The biological properties of the Wnt-8D are hereinafter referred to as "biological activity of Wnt-8D" or "Wnt-8D activity". Preferably, a polypeptide of the present invention exhibits at least one biological activity of Wnt-8D.

Polypeptides of the present invention also includes variants of the aforementioned polypeptides, including all allelic forms and splice variants. Such polypeptides vary from the reference polypeptide by insertions, deletions, and substitutions that may be conservative or non-conservative, or any combination thereof. Particularly preferred variants are those in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acids are inserted, substituted, or deleted, in any combination.

Preferred fragments of polypeptides of the present invention include a polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids from the amino acid sequence of SEQ ID NO: 2, or a polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids truncated or deleted from the amino acid sequence of SEQ ID NO: 2. Preferred fragments are biologically active fragments that mediate the biological activity of Wnt-8D, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also preferred are those fragments that are antigenic or immunogenic in an animal, especially in a human.

Fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these variants may be employed as intermediates for producing the full-length polypeptides of the invention. The polypeptides of

the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence that contains secretory or leader sequences, pro-sequences, sequences that aid in purification, for instance multiple histidine residues, or an additional sequence for stability during recombinant production.

Polypeptides of the present invention can be prepared in any suitable manner, for instance by isolation from naturally occurring sources, from genetically engineered host cells comprising expression systems (*vide infra*) or by chemical synthesis, using for instance automated peptide synthesisers, or a combination of such methods.. Means for preparing such polypeptides are well understood in the art.

In a further aspect, the present invention relates to Wnt-8D polynucleotides. Such polynucleotides include:

- (a) a polynucleotide comprising a polynucleotide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polynucleotide sequence of SEQ ID NO:1;
- (b) a polynucleotide comprising the polynucleotide of SEQ ID NO:1;
- (c) a polynucleotide having at least 95%, 96%, 97%, 98%, or 99% identity to the polynucleotide of SEQ ID NO:1;
- (d) the polynucleotide of SEQ ID NO:1;
- (e) a polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2;
- (f) a polynucleotide comprising a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2;
- (g) a polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2;
- (h) a polynucleotide encoding the polypeptide of SEQ ID NO:2;

- 7 -

(i) a polynucleotide having or comprising a polynucleotide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polynucleotide sequence of SEQ ID NO:1;

5 (j) a polynucleotide having or comprising a polynucleotide sequence encoding a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to the polypeptide sequence of SEQ ID NO:2; and

10 polynucleotides that are fragments and variants of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.

Preferred fragments of polynucleotides of the present invention include a polynucleotide comprising an nucleotide sequence having at least 15, 30, 50 or 100 contiguous nucleotides from the sequence of SEQ ID NO: 1, or
15 a polynucleotide comprising an sequence having at least 30, 50 or 100 contiguous nucleotides truncated or deleted from the sequence of SEQ ID NO: 1.

Preferred variants of polynucleotides of the present invention include splice variants, allelic variants, and polymorphisms, including polynucleotides having one or more single nucleotide polymorphisms (SNPs).
20

Polynucleotides of the present invention also include polynucleotides encoding polypeptide variants that comprise the amino acid sequence of SEQ ID NO:2 and in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1
25 amino acid residues are substituted, deleted or added, in any combination.

In a further aspect, the present invention provides polynucleotides that are RNA transcripts of the DNA sequences of the present invention. Accordingly, there is provided an RNA polynucleotide that:

30 (a) comprises an RNA transcript of the DNA sequence encoding the polypeptide of SEQ ID NO:2;

(b) is the RNA transcript of the DNA sequence encoding the polypeptide of SEQ ID NO:2;

(c) comprises an RNA transcript of the DNA sequence of SEQ ID NO:1; or

(d) is the RNA transcript of the DNA sequence of SEQ ID NO:1;

and RNA polynucleotides that are complementary thereto.

5

The polynucleotide sequence of SEQ ID NO:1 shows homology with MMWNT8DPT (Bouillet, P. et al., direct submission Genbank; unpublished). The polynucleotide sequence of SEQ ID NO:1 is a cDNA sequence that encodes the polypeptide of SEQ ID NO:2. The polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence of SEQ ID NO:1 or it may be a sequence other than SEQ ID NO:1, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2. The polypeptide of the SEQ ID NO:2 is related to other proteins of the wingless/int family, having homology and/or structural similarity with MWN8D_MOUSE (Bouillet, P. et al., Mech. Dev. 58, 141-152, 1996).

10

15

20

Preferred polypeptides and polynucleotides of the present invention are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one Wnt-8D activity.

25

30

Polynucleotides of the present invention may be obtained using standard cloning and screening techniques from a cDNA library derived from mRNA in cells of human bone marrow, brain, colon, heart, kidney, lung, muscle, kidney, pancreas, prostate, uterus and fetal tissue, (see for instance, Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

When polynucleotides of the present invention are used for the recombinant production of polypeptides of the present invention, the polynucleotide may include the coding sequence for the mature polypeptide, by itself, or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

Polynucleotides that are identical, or have sufficient identity to a polynucleotide sequence of SEQ ID NO:1, may be used as hybridization probes for cDNA and genomic DNA or as primers for a nucleic acid amplification reaction (for instance, PCR). Such probes and primers may be used to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes (including genes encoding paralogs from human sources and orthologs and paralogs from species other than human) that have a high sequence similarity to SEQ ID NO:1, typically at least 95% identity. Preferred probes and primers will generally comprise at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50, if not at least 100 nucleotides. Particularly preferred probes will have between 30 and 50 nucleotides. Particularly preferred primers will have between 20 and 25 nucleotides.

A polynucleotide encoding a polypeptide of the present invention, including homologs from species other than human, may be obtained by a process comprising the steps of screening a library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof, preferably of at least 15 nucleotides; and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybridization techniques are well known to the skilled artisan. Preferred stringent hybridization conditions include overnight incubation at

42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA; followed by washing the filters in 0.1x SSC at about 65°C. Thus the present invention also includes isolated polynucleotides, preferably with a nucleotide sequence of at least 100, obtained by screening a library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 or a fragment thereof, preferably of at least 15 nucleotides.

The skilled artisan will appreciate that, in many cases, an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide does not extend all the way through to the 5' terminus. This is a consequence of reverse transcriptase, an enzyme with inherently low "processivity" (a measure of the ability of the enzyme to remain attached to the template during the polymerisation reaction), failing to complete a DNA copy of the mRNA template during first strand cDNA synthesis.

There are several methods available and well known to those skilled in the art to obtain full-length cDNAs, or extend short cDNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman et al., Proc Nat Acad Sci USA 85, 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon (trade mark) technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon (trade mark) technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the "missing" 5' end of the cDNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using 'nested' primers, that is, primers designed to anneal within the amplified product (typically an adaptor specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the known gene sequence). The products of this reaction can then be analysed by DNA sequencing and a full-length cDNA constructed either by joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.

Recombinant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems comprising a polynucleotide or polynucleotides of the present invention, to host cells which are genetically engineered with such expression systems and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Polynucleotides may be introduced into host cells by methods described in many standard laboratory manuals, such as Davis et al., Basic Methods in Molecular Biology (1986) and Sambrook *et al.*(*ibid*). Preferred methods of introducing polynucleotides into host cells include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as *Streptococci*, *Staphylococci*, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as

- 12 -

cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector that is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host may be used. The appropriate polynucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, (*ibid*). Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.

If a polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis, isolation and/or purification.

Polynucleotides of the present invention may be used as diagnostic reagents, through detecting mutations in the associated gene. Detection of a mutated form of the gene characterised by the polynucleotide of SEQ ID NO:1 in the cDNA or genomic sequence and which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression

- 13 -

of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques well known in the art.

5 Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or it may be amplified enzymatically by using PCR, preferably RT-PCR, or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by
10 hybridizing amplified DNA to labeled Wnt-8D nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence difference may also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (see, for instance, Myers
15 *et al.*, Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc Natl Acad Sci USA (1985) 85: 4397-4401).

20 An array of oligonucleotide probes comprising Wnt-8D polynucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Such arrays are preferably high density arrays or grids. Array technology methods are well known and have general applicability and can be used to address a variety of
25 questions in molecular genetics including gene expression, genetic linkage, and genetic variability, see, for example, M.Chee *et al.*, Science, 274, 610-613 (1996) and other references cited therein.

Detection of abnormally decreased or increased levels of polypeptide or mRNA expression may also be used for diagnosing or determining
30 susceptibility of a subject to a disease of the invention. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization
35 methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived

from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

Thus in another aspect, the present invention relates to a diagnostic kit comprising:

(a) a polynucleotide of the present invention, preferably the nucleotide sequence of SEQ ID NO: 1, or a fragment or an RNA transcript thereof;

(b) a nucleotide sequence complementary to that of (a);

(c) a polypeptide of the present invention, preferably the polypeptide of SEQ ID NO:2 or a fragment thereof; or

(d) an antibody to a polypeptide of the present invention, preferably to the polypeptide of SEQ ID NO:2.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly diseases of the invention, amongst others.

The polynucleotide sequences of the present invention are valuable for chromosome localisation studies. The sequence is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (co-inheritance of physically adjacent genes). Precise human chromosomal localisations for a genomic sequence (gene fragment etc.) can be determined using Radiation Hybrid (RH) Mapping (Walter, M. Spillett, D., Thomas, P., Weissenbach, J., and Goodfellow, P.,

26474-677

- 15 -

(1994) A method for constructing radiation hybrid maps of whole genomes, *Nature Genetics* 7, 22-28). A number of RH panels are available from Research Genetics (Huntsville, AL, USA) e.g. the GeneBridge4 RH panel (*Hum Mol Genet* 1996 Mar;5(3):339-46 A radiation hybrid map of the human genome. Gyapay G, Schmitt K, Fizames C, Jones H, Vega-Czarny N, Spillett D, Muselet D, Prud'Homme JF, Dib C, Auffray C, Morissette J, Weissenbach J, Goodfellow PN). To determine the chromosomal location of a gene using this panel, 93 PCRs are performed using primers designed from the gene of interest on RH DNAs. Each of these DNAs contains random human genomic fragments maintained in a hamster background (human / hamster hybrid cell lines). These PCRs result in 93 scores indicating the presence or absence of the PCR product of the gene of interest. These scores are compared with scores created using PCR products from genomic sequences of known location. This comparison is conducted at the Broad Institute. The gene of the present invention maps to human chromosome 5q31 - 5q33 (D5S500 - D5S436).

The polynucleotide sequences of the present invention are also valuable tools for tissue expression studies. Such studies allow the determination of expression patterns of polynucleotides of the present invention which may give an indication as to the expression patterns of the encoded polypeptides in tissues, by detecting the mRNAs that encode them. The techniques used are well known in the art and include in situ hybridisation techniques to clones arrayed on a grid, such as cDNA microarray hybridisation (Schena *et al*, *Science*, 270, 467-470, 1995 and Shalon *et al*, *Genome Res*, 6, 639-645, 1996) and nucleotide amplification techniques such as PCR. A preferred method uses the TAQMAN (Trade mark) technology available from Perkin Elmer. Results from these studies can provide an indication of the normal function of the polypeptide in the organism. In addition, comparative studies of the normal expression pattern of mRNAs with that of mRNAs encoded by an alternative form of the same gene (for example, one having an alteration in polypeptide coding potential or a regulatory mutation) can provide valuable insights into the role of the polypeptides of the present invention, or that of inappropriate expression thereof in disease. Such inappropriate expression may be of a temporal, spatial or simply quantitative nature.

The polypeptides of the present invention are expressed in bone marrow, brain, colon, heart, kidney, lung, muscle, kidney, pancreas, prostate, uterus and fetal tissue.

5 A further aspect of the present invention relates to antibodies. The polypeptides of the invention or their fragments, or cells expressing them, can be used as immunogens to produce antibodies that are immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the
10 polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against polypeptides of the present invention may be obtained by administering the polypeptides or epitope-bearing fragments, or cells to an animal, preferably a non-human animal, using routine protocols.
15 For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., Nature (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, Immunology Today (1983) 4:72) and
20 the EBV-hybridoma technique (Cole *et al.*, Monoclonal Antibodies and Cancer Therapy, 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic
25 mice, or other organisms, including other mammals, may be used to express humanized antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography. Antibodies against polypeptides of the present invention
30 may also be employed to treat diseases of the invention, amongst others.

Polypeptides and polynucleotides of the present invention may also be used as vaccines. Accordingly, in a further aspect, the present invention

- 17 -

relates to a method for inducing an immunological response in a mammal that comprises inoculating the mammal with a polypeptide of the present invention, adequate to produce antibody and/or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said animal from disease, whether that disease is already established within the individual or not. An immunological response in a mammal may also be induced by a method comprises delivering a polypeptide of the present invention *via* a vector directing expression of the polynucleotide and coding for the polypeptide *in vivo* in order to induce such an immunological response to produce antibody to protect said animal from diseases of the invention. One way of administering the vector is by accelerating it into the desired cells as a coating on particles or otherwise. Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid. For use a vaccine, a polypeptide or a nucleic acid vector will be normally provided as a vaccine formulation (composition). The formulation may further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions that may contain anti-oxidants, buffers, bacteriostats and solutes that render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions that may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

Polypeptides of the present invention have one or more biological functions that are of relevance in one or more disease states, in particular the diseases of the invention hereinbefore mentioned. It is therefore useful to to identify compounds that stimulate or inhibit the function or level of the

polypeptide. Accordingly, in a further aspect, the present invention provides for a method of screening compounds to identify those that stimulate or inhibit the function or level of the polypeptide. Such methods identify agonists or antagonists that may be employed for therapeutic and prophylactic purposes for such diseases of the invention as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, collections of chemical compounds, and natural product mixtures. Such agonists or antagonists so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the polypeptide; a structural or functional mimetic thereof (see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)) or a small molecule.

The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof, by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve measuring or detecting (qualitatively or quantitatively) the competitive binding of a candidate compound to the polypeptide against a labeled competitor (e.g. agonist or antagonist). Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring a Wnt-8D activity in the mixture, and comparing the Wnt-8D activity of the mixture to a control mixture which contains no candidate compound.

Polypeptides of the present invention may be employed in conventional low capacity screening methods and also in high-throughput screening (HTS) formats. Such HTS formats include not only the well-established use of 96- and, more recently, 384-well micotiter plates but also emerging methods such as the nanowell method described by Schullek *et al.*, Anal Biochem., 246, 20-29, (1997).

- 19 -

Fusion proteins, such as those made from Fc portion and Wnt-8D polypeptide, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D. Bennett *et al.*, J Mol Recognition, 8:52-58 (1995); and K. Johanson *et al.*, J Biol Chem, 270(16):9459-9471 (1995)).

Screening techniques

The polynucleotides, polypeptides and antibodies to the polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents that may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

A polypeptide of the present invention may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance, ^{125}I), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists and antagonists of the polypeptide that compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

Examples of antagonists of polypeptides of the present invention include antibodies or, in some cases, oligonucleotides or proteins that are closely related to the ligands, substrates, receptors, enzymes, etc., as the case

- 20 -

may be, of the polypeptide, *e.g.*, a fragment of the ligands, substrates, receptors, enzymes, etc.; or a small molecule that bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.

5 Screening methods may also involve the use of transgenic technology and Wnt-8D gene. The art of constructing transgenic animals is well established. For example, the Wnt-8D gene may be introduced through microinjection into the male pronucleus of fertilized oocytes, retroviral transfer into pre- or post-implantation embryos, or injection of genetically modified, such as by electroporation, embryonic stem cells into host
10 blastocysts. Particularly useful transgenic animals are so-called "knock-in" animals in which an animal gene is replaced by the human equivalent within the genome of that animal. Knock-in transgenic animals are useful in the drug discovery process, for target validation, where the compound is specific for the human target. Other useful transgenic animals are so-called "knock-out" animals in which the expression of the animal ortholog of a polypeptide of the present invention and encoded by an endogenous DNA sequence in a cell is partially or completely annulled. The gene knock-out may be targeted to specific cells or tissues, may occur only in
15 certain cells or tissues as a consequence of the limitations of the technology, or may occur in all, or substantially all, cells in the animal. Transgenic animal technology also offers a whole animal expression-cloning system in which introduced genes are expressed to give large amounts of polypeptides of the present invention

25 Screening kits for use in the above described methods form a further aspect of the present invention. Such screening kits comprise:

- (a) a polypeptide of the present invention;
- (b) a recombinant cell expressing a polypeptide of the present invention;
- (c) a cell membrane expressing a polypeptide of the present invention; or
- 30 (d) an antibody to a polypeptide of the present invention;

which polypeptide is preferably that of SEQ ID NO:2.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

Glossary

The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

5 "Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an

Fab or other immunoglobulin expression library.

10 "Isolated" means altered "by the hand of man" from its natural state, *i.e.*, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Moreover,
15 a polynucleotide or polypeptide that is introduced into an organism by transformation, genetic manipulation or by any other recombinant method is "isolated" even if it is still present in said organism, which organism may be living or non-living.

20 "Polynucleotide" generally refers to any polyribonucleotide (RNA) or polydeoxribonucleotide (DNA), which may be unmodified or modified RNA or DNA. "Polynucleotides" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules
25 comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also includes DNAs or RNAs containing one or more modified bases and
30 DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in

- 22 -

nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

5 "Polypeptide" refers to any polypeptide comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids.

10 "Polypeptides" include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature.

15 Modifications may occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications.

20 Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, biotinylation, covalent attachment

25 of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to

30 proteins such as arginylation, and ubiquitination (see, for instance, Proteins - Structure and Molecular Properties, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., Post-translational Protein Modifications: Perspectives and Prospects, 1-12, in

35

Post-translational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", Meth Enzymol, 182, 626-646, 1990, and Rattan *et al.*, "Protein Synthesis: Post-translational Modifications and Aging", Ann NY Acad Sci, 663, 48-62, 1992).

"Fragment" of a polypeptide sequence refers to a polypeptide sequence that is shorter than the reference sequence but that retains essentially the same biological function or activity as the reference polypeptide. "Fragment" of a polynucleotide sequence refers to a polynucleotide sequence that is shorter than the reference sequence of SEQ ID NO:1..

"Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains the essential properties thereof. A typical variant of a polynucleotide differs in nucleotide sequence from the reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from the reference polypeptide. Generally, alterations are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, insertions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. Typical conservative substitutions include Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe and Tyr. A variant of a polynucleotide or polypeptide may be naturally occurring such as an allele, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis. Also included as variants are polypeptides having one or more post-translational modifications, for instance glycosylation, phosphorylation, methylation, ADP ribosylation and the like. Embodiments include methylation of the N-terminal amino acid, phosphorylations of serines and threonines and modification of C-terminal glycines.

- 24 -

"Allele" refers to one of two or more alternative forms of a gene occurring at a given locus in the genome.

"Polymorphism" refers to a variation in nucleotide sequence (and encoded polypeptide sequence, if relevant) at a given position in the genome within a population.

"Single Nucleotide Polymorphism" (SNP) refers to the occurrence of nucleotide variability at a single nucleotide position in the genome, within a population. An SNP may occur within a gene or within intergenic regions of the genome. SNPs can be assayed using Allele Specific Amplification (ASA). For the process at least 3 primers are required. A common primer is used in reverse complement to the polymorphism being assayed. This common primer can be between 50 and 1500 bps from the polymorphic base. The other two (or more) primers are identical to each other except that the final 3' base wobbles to match one of the two (or more) alleles that make up the polymorphism. Two (or more) PCR reactions are then conducted on sample DNA, each using the common primer and one of the Allele Specific Primers.

"Splice Variant" as used herein refers to cDNA molecules produced from RNA molecules initially transcribed from the same genomic DNA sequence but which have undergone alternative RNA splicing. Alternative RNA splicing occurs when a primary RNA transcript undergoes splicing, generally for the removal of introns, which results in the production of more than one mRNA molecule each of that may encode different amino acid sequences. The term splice variant also refers to the proteins encoded by the above cDNA molecules.

"Identity" reflects a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, determined by comparing the sequences. In general, identity refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of the two polynucleotide or two polypeptide sequences, respectively, over the length of the sequences being compared.

"% Identity" - For sequences where there is not an exact correspondence, a "% identity" may be determined. In general, the two sequences to be compared are aligned to give a maximum correlation between the sequences. This may include inserting "gaps" in either one

- 25 -

or both sequences, to enhance the degree of alignment. A % identity may be determined over the whole length of each of the sequences being compared (so-called global alignment), that is particularly suitable for sequences of the same or very similar length, or over shorter, defined lengths (so-called local alignment), that is more suitable for sequences of unequal length.

"Similarity" is a further, more sophisticated measure of the relationship between two polypeptide sequences. In general, "similarity" means a comparison between the amino acids of two polypeptide chains, on a residue by residue basis, taking into account not only exact correspondences between a between pairs of residues, one from each of the sequences being compared (as for identity) but also, where there is not an exact correspondence, whether, on an evolutionary basis, one residue is a likely substitute for the other. This likelihood has an associated "score" from which the "% similarity" of the two sequences can then be determined.

Methods for comparing the identity and similarity of two or more sequences are well known in the art. Thus for instance, programs available in the Wisconsin Sequence Analysis Package, version 9.1 (Devereux J et al, Nucleic Acids Res, 12, 387-395, 1984, available from Genetics Computer Group, Madison, Wisconsin, USA), for example the programs BESTFIT and GAP, may be used to determine the % identity between two polynucleotides and the % identity and the % similarity between two polypeptide sequences. BESTFIT uses the "local homology" algorithm of Smith and Waterman (J Mol Biol, 147,195-197, 1981, Advances in Applied Mathematics, 2, 482-489, 1981) and finds the best single region of similarity between two sequences. BESTFIT is more suited to comparing two polynucleotide or two polypeptide sequences that are dissimilar in length, the program assuming that the shorter sequence represents a portion of the longer. In comparison, GAP aligns two sequences, finding a "maximum similarity", according to the algorithm of Neddleman and Wunsch (J Mol Biol, 48, 443-453, 1970). GAP is more suited to comparing sequences that are approximately the same length and an alignment is expected over the entire length. Preferably, the parameters "Gap Weight" and "Length Weight" used in each program are 50 and 3, for polynucleotide sequences and 12 and 4 for polypeptide sequences, respectively. Preferably, % identities and

- 26 -

similarities are determined when the two sequences being compared are optimally aligned.

Other programs for determining identity and/or similarity between sequences are also known in the art, for instance the BLAST family of programs (Altschul S F et al, J Mol Biol, 215, 403-410, 1990, Altschul S F et al, Nucleic Acids Res., 25:389-3402, 1997, available from the National Center for Biotechnology Information (NCBI), Bethesda, Maryland, USA and accessible through the home page of the NCBI at www.ncbi.nlm.nih.gov) and FASTA (Pearson W R, Methods in Enzymology, 183, 63-99, 1990; Pearson W R and Lipman D J, Proc Nat Acad Sci USA, 85, 2444-2448, 1988, available as part of the Wisconsin Sequence Analysis Package).

Preferably, the BLOSUM62 amino acid substitution matrix (Henikoff S and Henikoff J G, Proc. Nat. Acad Sci. USA, 89, 10915-10919, 1992) is used in polypeptide sequence comparisons including where nucleotide sequences are first translated into amino acid sequences before comparison.

Preferably, the program BESTFIT is used to determine the % identity of a query polynucleotide or a polypeptide sequence with respect to a reference polynucleotide or a polypeptide sequence, the query and the reference sequence being optimally aligned and the parameters of the program set at the default value, as hereinbefore described.

"Identity Index" is a measure of sequence relatedness which may be used to compare a candidate sequence (polynucleotide or polypeptide) and a reference sequence. Thus, for instance, a candidate polynucleotide sequence having, for example, an Identity Index of 0.95 compared to a reference polynucleotide sequence is identical to the reference sequence except that the candidate polynucleotide sequence may include on average up to five differences per each 100 nucleotides of the reference sequence. Such differences are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion. These differences may occur at the 5' or 3' terminal positions of the reference polynucleotide sequence or anywhere between these terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or

- 27 -

more contiguous groups within the reference sequence. In other words, to obtain a polynucleotide sequence having an Identity Index of 0.95 compared to a reference polynucleotide sequence, an average of up to 5 in every 100 of the nucleotides of the in the reference sequence may be
 5 deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

Similarly, for a polypeptide, a candidate polypeptide sequence having, for example, an Identity Index of 0.95 compared to a reference polypeptide
 10 sequence is identical to the reference sequence except that the polypeptide sequence may include an average of up to five differences per each 100 amino acids of the reference sequence. Such differences are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative
 15 substitution, or insertion. These differences may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between these terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. In other
 20 words, to obtain a polypeptide sequence having an Identity Index of 0.95 compared to a reference polypeptide sequence, an average of up to 5 in every 100 of the amino acids in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other values of the
 25 Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

The relationship between the number of nucleotide or amino acid differences and the Identity Index may be expressed in the following equation:

$$n_a \leq x_a - (x_a \cdot I),$$

30 in which:

n_a is the number of nucleotide or amino acid differences,

x_a is the total number of nucleotides or amino acids in SEQ ID NO:1 or SEQ ID NO:2, respectively,

26474-677

- 28 -

I is the Identity Index ,

• is the symbol for the multiplication operator, and

in which any non-integer product of x_a and I is rounded down to the nearest integer prior to subtracting it from x_a .

5 "Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a reference sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the two sequences as hereinbefore defined. Falling within this generic term are
10 the terms "ortholog", and "paralog". "Ortholog" refers to a polynucleotide or polypeptide that is the functional equivalent of the polynucleotide or polypeptide in another species. "Paralog" refers to a polynucleotide or polypeptide that within the same species which is functionally similar.

15 "Fusion protein" refers to a protein encoded by two, unrelated, fused genes or fragments thereof. Examples have been disclosed in US 5541087, 5726044. In the case of Fc-Wnt-8D, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for performing the functional expression of Fc-Wnt-8D or fragments of Wnt-8D, to improve pharmacokinetic properties of such a fusion protein
20 when used for therapy and to generate a dimeric Wnt-8D. The Fc-Wnt-8D DNA construct comprises in 5' to 3' direction, a secretion cassette, i.e. a signal sequence that triggers export from a mammalian cell, DNA encoding an immunoglobulin Fc region fragment, as a fusion partner, and a DNA encoding Wnt-8D or fragments thereof. In some uses it would be
25 desirable to be able to alter the intrinsic functional properties (complement binding, Fc-Receptor binding) by mutating the functional Fc sides while leaving the rest of the fusion protein untouched or delete the Fc part completely after expression.

- 1 -

SEQUENCE LISTING

<110> Merck Patent GmbH

5 <120> New wingless gene Wnt-8D

<130> WNT8dKDWS

<140>

10 <141>

<160> 2

<170> PatentIn Ver. 2.1

15

<210> 1

<211> 1650

<212> DNA

<213> Homo sapiens

20

<220>

<221> CDS

<222> (100)..(1155)

25 <400> 1

agaattttct cacataaata ctgaggaaga cctgccctc tcctcactcc tctggacttg 60

gccctgagct ggacctgggc cactggggta ggcagggcg atg ggg aac ctg ttt 114
 Met Gly Asn Leu Phe
 1 5

30

atg ctc tgg gca gct ctg ggc ata tgc tgt gct gca ttc agt gcc tct 162
 Met Leu Trp Ala Ala Leu Gly Ile Cys Cys Ala Ala Phe Ser Ala Ser
 10 15 20

35

gcc tgg tca gtg aac aat ttc ctg ata aca ggt ccc aag gcc tat ctg 210
 Ala Trp Ser Val Asn Asn Phe Leu Ile Thr Gly Pro Lys Ala Tyr Leu
 25 30 35

40

acc tac acg act agt gtg gcc ttg ggt gcc cag agt ggc atc gag gag 258
 Thr Tyr Thr Thr Ser Val Ala Leu Gly Ala Gln Ser Gly Ile Glu Glu
 40 45 50

45

tgc aag ttc cag ttt gct tgg gaa cgc tgg aac tgc cct gaa aat gct 306
 Cys Lys Phe Gln Phe Ala Trp Glu Arg Trp Asn Cys Pro Glu Asn Ala
 55 60 65

50

ctt cag ctc tcc acc cac aac agg ctg aga agt gct acc aga gag act 354
 Leu Gln Leu Ser Thr His Asn Arg Leu Arg Ser Ala Thr Arg Glu Thr
 70 75 80 85

55

tcc ttc ata cat gct atc agc tct gct gga gtc atg tac atc atc acc 402
 Ser Phe Ile His Ala Ile Ser Ser Ala Gly Val Met Tyr Ile Ile Thr
 90 95 100

aag aac tgt agc atg ggt gac ttc gaa aac tgt ggc tgt gat ggg tca 450
 Lys Asn Cys Ser Met Gly Asp Phe Glu Asn Cys Gly Cys Asp Gly Ser
 105 110 115

60

- 2 -

	aac aat gga aaa aca gga ggc cat ggc tgg atc tgg gga ggc tgc agc	498
	Asn Asn Gly Lys Thr Gly Gly His Gly Trp Ile Trp Gly Gly Cys Ser	
	120 125 130	
5	gac aat gtg gaa ttt ggg gaa agg atc tcc aaa ctc ttt gtg gac agt	546
	Asp Asn Val Glu Phe Gly Glu Arg Ile Ser Lys Leu Phe Val Asp Ser	
	135 140 145	
10	ttg gag aag ggg aag gat gcc aga gcc ctg atg aat ctt cac aac aac	594
	Leu Glu Lys Gly Lys Asp Ala Arg Ala Leu Met Asn Leu His Asn Asn	
	150 155 160 165	
15	agg gcc ggc aga ctg gca gtg aga gcc acc atg aaa agg aca tgc aaa	642
	Arg Ala Gly Arg Leu Ala Val Arg Ala Thr Met Lys Arg Thr Cys Lys	
	170 175 180	
20	tgt cat ggc atc tct ggg agc tgc agc ata cag aca tgc tgg ctg cag	690
	Cys His Gly Ile Ser Gly Ser Cys Ser Ile Gln Thr Cys Trp Leu Gln	
	185 190 195	
25	ctg gct gaa ttc cgg gag atg gga gac tac cta aag gcc aag tat gac	738
	Leu Ala Glu Phe Arg Glu Met Gly Asp Tyr Leu Lys Ala Lys Tyr Asp	
	200 205 210	
30	cag gcg ctg aaa att gaa atg gat aag cgg cag ctg aga gct ggg aac	786
	Gln Ala Leu Lys Ile Glu Met Asp Lys Arg Gln Leu Arg Ala Gly Asn	
	215 220 225	
35	agc gcc gag ggc cac tgg gtg ccc gct gag gcc ttc ctt cct agc gca	834
	Ser Ala Glu Gly His Trp Val Pro Ala Glu Ala Phe Leu Pro Ser Ala	
	230 235 240 245	
40	gag gcg gaa ctg atc ttt tta gag gaa tca cca gat tac tgt acc tgc	882
	Glu Ala Glu Leu Ile Phe Leu Glu Glu Ser Pro Asp Tyr Cys Thr Cys	
	250 255 260	
45	aat tcc agc ctg ggc atc tat ggc aca gag ggt cgt gag tgc cta cag	930
	Asn Ser Ser Leu Gly Ile Tyr Gly Thr Glu Gly Arg Glu Cys Leu Gln	
	265 270 275	
50	aac agc cac aac aca tcc agg tgg gag cga cgt agc tgt ggg cgc ctg	978
	Asn Ser His Asn Thr Ser Arg Trp Glu Arg Arg Ser Cys Gly Arg Leu	
	280 285 290	
55	tgc act gag tgt ggg ctg cag gtg gaa gag agg aaa act gag gtc ata	1026
	Cys Thr Glu Cys Gly Leu Gln Val Glu Glu Arg Lys Thr Glu Val Ile	
	295 300 305	
60	agc agc tgt aac tgc aaa ttc cag tgg tgc tgt acg gtc aag tgt gac	1074
	Ser Ser Cys Asn Cys Lys Phe Gln Trp Cys Cys Thr Val Lys Cys Asp	
	310 315 320 325	
65	cag tgt agg cat gtg gtg agc aag tat tac tgc gca cgc tcc cca ggc	1122
	Gln Cys Arg His Val Val Ser Lys Tyr Tyr Cys Ala Arg Ser Pro Gly	
	330 335 340	
70	agt gcc cag tcc ctg ggt aag ggc agt gcc tga taatacccca cacaagttca	1175
	Ser Ala Gln Ser Leu Gly Lys Gly Ser Ala	
	345 350	
75	cttgattaat tgcattcagtg gaaggggaca tagcttctct cttagagaga acagattgga	1235

- 3 -

aagcaatcgg aaaattgcag ttttgggtctg tagtcctcat gatatactgct atcagtgggg 1295
 aaaatggagg cccaagattc tacagcatat tcctggcggg gctgaaattg gaacctgggc 1355
 5 ctctgactt tggcagaccc ccatttcac tttcctgcaa actactttcc catctttgtg 1415
 cctgtactta tgcagctttc tacagggaga gtttggtttg gggctctatat ctagaggac 1475
 10 cttcaaagta tttgttcctt taaatttcag accatgtcca acccagctgt gctgctggga 1535
 atcaggagaa tagaagcaaa aaacgaaaga gttctgttca gacttctgaa gagcagcctg 1595
 tggctacaaa tctatgctga taaatgaggt aaagaccaca tatctgccta ctgga 1650
 15

<210> 2

<211> 351

<212> PRT

20 <213> Homo sapiens

<400> 2

	Met	Gly	Asn	Leu	Phe	Met	Leu	Trp	Ala	Ala	Leu	Gly	Ile	Cys	Cys	Ala
	1				5				10					15		
25	Ala	Phe	Ser	Ala	Ser	Ala	Trp	Ser	Val	Asn	Asn	Phe	Leu	Ile	Thr	Gly
				20				25					30			
	Pro	Lys	Ala	Tyr	Leu	Thr	Tyr	Thr	Thr	Ser	Val	Ala	Leu	Gly	Ala	Gln
			35				40					45				
	Ser	Gly	Ile	Glu	Glu	Cys	Lys	Phe	Gln	Phe	Ala	Trp	Glu	Arg	Trp	Asn
30		50					55				60					
	Cys	Pro	Glu	Asn	Ala	Leu	Gln	Leu	Ser	Thr	His	Asn	Arg	Leu	Arg	Ser
	65					70				75						80
	Ala	Thr	Arg	Glu	Thr	Ser	Phe	Ile	His	Ala	Ile	Ser	Ser	Ala	Gly	Val
				85				90						95		
35	Met	Tyr	Ile	Ile	Thr	Lys	Asn	Cys	Ser	Met	Gly	Asp	Phe	Glu	Asn	Cys
			100					105						110		
	Gly	Cys	Asp	Gly	Ser	Asn	Asn	Gly	Lys	Thr	Gly	Gly	His	Gly	Trp	Ile
		115					120					125				
	Trp	Gly	Gly	Cys	Ser	Asp	Asn	Val	Glu	Phe	Gly	Glu	Arg	Ile	Ser	Lys
40		130					135					140				
	Leu	Phe	Val	Asp	Ser	Leu	Glu	Lys	Gly	Lys	Asp	Ala	Arg	Ala	Leu	Met
	145					150					155					160
	Asn	Leu	His	Asn	Asn	Arg	Ala	Gly	Arg	Leu	Ala	Val	Arg	Ala	Thr	Met
				165				170							175	
45	Lys	Arg	Thr	Cys	Lys	Cys	His	Gly	Ile	Ser	Gly	Ser	Cys	Ser	Ile	Gln
			180					185						190		
	Thr	Cys	Trp	Leu	Gln	Leu	Ala	Glu	Phe	Arg	Glu	Met	Gly	Asp	Tyr	Leu
		195					200					205				
	Lys	Ala	Lys	Tyr	Asp	Gln	Ala	Leu	Lys	Ile	Glu	Met	Asp	Lys	Arg	Gln
50		210					215					220				
	Leu	Arg	Ala	Gly	Asn	Ser	Ala	Glu	Gly	His	Trp	Val	Pro	Ala	Glu	Ala
	225					230					235					240
	Phe	Leu	Pro	Ser	Ala	Glu	Ala	Glu	Leu	Ile	Phe	Leu	Glu	Glu	Ser	Pro
				245						250					255	
55	Asp	Tyr	Cys	Thr	Cys	Asn	Ser	Ser	Leu	Gly	Ile	Tyr	Gly	Thr	Glu	Gly
			260						265					270		
	Arg	Glu	Cys	Leu	Gln	Asn	Ser	His	Asn	Thr	Ser	Arg	Trp	Glu	Arg	Arg
			275					280					285			
	Ser	Cys	Gly	Arg	Leu	Cys	Thr	Glu	Cys	Gly	Leu	Gln	Val	Glu	Glu	Arg
60		290					295					300				
	Lys	Thr	Glu	Val	Ile	Ser	Ser	Cys	Asn	Cys	Lys	Phe	Gln	Trp	Cys	Cys

WO 01/83543

PCT/EP01/04887

- 4 -

305					310					315					320
Thr	Val	Lys	Cys	Asp	Gln	Cys	Arg	His	Val	Val	Ser	Lys	Tyr	Tyr	Cys
				325						330					335
Ala	Arg	Ser	Pro	Gly	Ser	Ala	Gln	Ser	Leu	Gly	Lys	Gly	Ser	Ala	
5			340					345					350		

26474-677

- 29 -

CLAIMS:

1. An isolated human wingless/int 8D (Wnt-8D) polypeptide comprising the polypeptide sequence of SEQ ID NO:2.
2. The isolated polypeptide of claim 1 consisting of the polypeptide
5 sequence of SEQ ID NO:2.
3. An isolated polynucleotide encoding human wingless/int 8D (Wnt-8D), comprising polynucleotides from nucleotide positions 100 to 1155 of SEQ ID NO: 1.
4. An isolated polynucleotide encoding a human wingless/int 8D (Wnt-8D) polypeptide, wherein said polypeptide comprises the polypeptide sequence of
10 SEQ ID NO: 2.
5. An isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the polynucleotide of SEQ ID NO:1;

(b) the polynucleotide of SEQ ID NO:1;

(c) a polynucleotide comprising a polynucleotide sequence encoding
15 the polypeptide of SEQ ID NO:2; and

(d) a polynucleotide encoding the polypeptide of SEQ ID NO:2.
6. An expression vector comprising the isolated polynucleotide of any one of claims 3 to 5.
7. An expression system comprising a polynucleotide capable of
20 producing the polypeptide of claim 1 or 2 when said expression system is present in a compatible host cell.
8. A recombinant host cell comprising the expression system of claim 7 or a membrane thereof expressing the polypeptide of claim 1 or 2.

26474-677

- 30 -

9. A process for producing the polypeptide of claim 1 or 2 comprising the step of culturing the host cell as defined in claim 8 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium.
- 5 10. A fusion protein comprising an Immunoglobulin Fc-region and the polypeptide of claim 1 or 2.
11. An antibody immunospecific for the polypeptide of claim 1 or 2.
12. An *in vitro* method for screening to identify compounds that stimulate or inhibit the function or level of the polypeptide of claim 1 or 2 comprising a method
10 selected from the group consisting of:
- (a) measuring, or detecting quantitatively or qualitatively, the binding of a candidate compound to the polypeptide, or to the cells or membranes expressing the polypeptide, or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound;
- 15 (b) measuring the competition of binding of a candidate compound to the polypeptide, or to the cells or membranes expressing the polypeptide, or a fusion protein thereof in the presence of a labeled competitor;
- (c) testing whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems
20 appropriate to the cells or cell membranes expressing the polypeptide;
- (d) mixing a candidate compound with a solution containing the polypeptide of claim 1 or 2, to form a mixture, measuring activity of the polypeptide in the mixture, and comparing the activity of the mixture to a control mixture which contains no candidate compound; and

26474-677

- 31 -

(e) detecting the effect of a candidate compound on the production of mRNA encoding said polypeptide or said polypeptide in cells, using an ELISA assay.